New business development based on short-term licorice cultivation technology
First written in FY2017-Q3. 4 of 9 entries say "Advanced", first in FY2018-Q1. Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1AdvancedAnnual report
「Through internal synergies, the company commercialized a Kampo medicine containing domestically grown licorice and conducted test sales in December 2024, then launched “鼻セレブ SKINLISM” facial cleansing soap containing licorice extract in March 2025.」
Following the establishment of large-scale licorice cultivation technology, the company expanded applications by commercializing and test-marketing a Kampo medicine containing domestically grown licorice and launching facial cleansing soap. - FY2025-H1AchievedAnnual report
「The company has also successfully established large-scale cultivation technology for licorice, a medicinal plant widely used in pharmaceuticals, cosmetics and food products. By domesticating production rather than relying on wild-harvested supplies from overseas, the company will ensure high traceability and pursue a safe, secure and sustainable business.」
The company states that it has successfully established large-scale cultivation technology for licorice, progressing from the research and trial stage to the technology-establishment stage. - FY2024-Q3AdvancedAnnual report
「The company has reached the stage of establishing the technology for large-scale cultivation of licorice, a medicinal plant used in a wide range of applications, including pharmaceuticals and cosmetics.」
The company states that large-scale licorice cultivation has progressed from the research and trial stage to the stage where establishment of the technology is in sight. - FY2023-Q1RestatedAnnual report
「The company is also taking on new areas, including large-scale cultivation at 王子薬用植物研究所株式会社 aimed at ensuring a stable domestic supply of licorice, an imported ingredient for Kampo medicines.」
The company continues large-scale cultivation aimed at ensuring a stable domestic supply of licorice and continues to pursue new areas. - FY2019-Q1AdvancedAnnual report
「Through cultivation research on the medicinal plant licorice (甘草, kanzo), the company became the first in Japan to develop short-term cultivation technology that meets the active-ingredient content requirements set out in the 17th revised Japanese Pharmacopoeia, and began large-scale cultivation trials aimed at domestic mass production of licorice, which is currently dependent on imports.」
For licorice, the initiative has progressed from developing short-term cultivation technology to launching large-scale cultivation trials aimed at domestic mass production. - FY2018-Q3RestatedAnnual report
「The company's cultivated licorice is expected to be commercialized as a cosmetic ingredient by 株式会社アルビオン. Going forward, the company will aim to sell it as a pharmaceutical ingredient for Kampo medicines and other products, while also focusing on it as one of the pillars of a new business, with a view to developing it as an ingredient for quasi-drugs and sweeteners.」
The company continues to pursue practical use of licorice as a cosmetic ingredient, as well as applications in pharmaceuticals, quasi-drugs and sweeteners. - FY2018-Q2RestatedAnnual report
「The company's cultivated licorice is expected to be commercialized as a cosmetic ingredient by 株式会社アルビオン. Going forward, the company will aim to sell it as a pharmaceutical ingredient for Kampo medicines and other products, while also focusing on it as one of the pillars of a new business, with a view to developing it as an ingredient for quasi-drugs and sweeteners.」
The company continues to pursue practical use as a cosmetic ingredient by 株式会社アルビオン, as well as applications in pharmaceuticals, quasi-drugs and sweeteners. - FY2018-Q1AdvancedAnnual report
「Through cultivation research on the medicinal plant licorice (甘草, kanzo), the company became the first in Japan to develop short-term cultivation technology that meets the active-ingredient content requirements set out in the 17th revised Japanese Pharmacopoeia. The company's cultivated licorice is expected to be commercialized as a cosmetic ingredient by 株式会社アルビオン. Going forward, the company will aim to sell it as a pharmaceutical ingredient for Kampo medicines and other products, while also focusing on it as one of the pillars of a new business, with a view to developing it as an ingredient for quasi-drugs and sweeteners.」
The initiative has progressed from developing short-term cultivation technology to the prospect of practical use as a cosmetic ingredient by 株式会社アルビオン, with potential applications in pharmaceuticals, quasi-drugs and sweeteners also indicated. - FY2017-Q3First statedAnnual report
「Through cultivation research on the medicinal plant licorice (甘草, kanzo), the company became the first in Japan to develop short-term cultivation technology that meets the active-ingredient content requirements set out in the 17th revised Japanese Pharmacopoeia. In addition to aiming to sell it as a pharmaceutical ingredient for Kampo medicines and other products, the company will focus on it as one of the pillars of a new business, with a view to developing it as an ingredient for daily-use products and cosmetics.」
The company recorded for the first time its policy of developing, for licorice, short-term cultivation technology in Japan that meets the required active-ingredient content and pursuing sales as a pharmaceutical ingredient and development as an ingredient for daily-use products and cosmetics as pillars of a new business.